Given the presence of AAV therapies in ongoing clinical trials (250 trials in 2021 [52]), the demonstrated AAV-mediated FOXO3 treatment might depict a starting point for further studies on the genetic treatment of sarcopenia. This evidence concerns the gene FOXO3 and sarcopenia.